^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    FoundationOne® CDx

    Company:
    Roche
    Type:
    FDA Approved (PMA)
    Related tests:
    almost3years
    Unique spectrum of BRAF alts in prostate cancer! 👉3% BRAF activated, mostly rearrangements and K601E. 👉Diverse BRAF fusions detected both in tissue DNA (F1CDx) and liquid ctDNA (F1LCDx). Love the teamwork here!🙌 @neerajaiims @montypal @EAntonarakis @HTukachinsky ()
    Circulating tumor DNA
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF fusion • BRAF K601E • BRAF K601
    |
    FoundationOne® CDx • FoundationOne® Liquid CDx
    over3years
    Our study shows that @FoundationOne CDx assay: TMB-H, benefit from immunotherapy in TMB-H tumors is in Category I cancer (melanoma, lung, etc.) and may have minimal benefit for many common Category II cancers, breast, prostate, and brain. #bcsm https://t.co/VaSrllLgOQ ()
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    |
    FoundationOne® CDx
    over3years
    Perhaps a TMB of 10 mut/Mb (by FoundationOne CDx) is too low a cutpoint to be used as a robust, clinically relevant biomarker for improved survival in NSCLC. ()
    Clinical
    |
    FoundationOne® CDx
    over3years
    FDA Approves FoundationOne CDx for EGFR Inhibitors to Identify EGFR Mutations in NSCLC https://t.co/l1GVKfKgVE ()
    FDA event
    |
    EGFR mutation
    |
    FoundationOne® CDx
    4years
    @ErikaHamilton9 ordered Foundation One testing for my sister, who has mTNBC. It came back with a TMB of 10. This is very interesting information! She has a virtual visit next week with Dr. Hamilton. So glad to have expert eyes on her case! 👀❤️ (@amyr08)
    FoundationOne® CDx
    almost5years
    #TumorMutationalBurden a #Predictive #Biomarker in #SolidTumors https://t.co/a4YBRrJgwm #Oncology #MolecularOncology #PrecisionOncology #Immunotherapy #PDL1 #NGS #WholeExomeSequencing #MSKImpact #FoundationOneCDx #Mutation #Somatic #Melanoma #LungCancer @FASinicropeMD @AACR (@MDJDPathology)
    Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Next-generation sequencing
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    FoundationOne® CDx • MSK-IMPACT
    almost5years
    #Chugai Obtains Approval for Expanded Use of #FoundationOne CDx #Cancer Genomic Profile as a #CompanionDiagnostic for #Olaparib in #BRCAMutated #ProstateCancer https://t.co/daVKZYsZjF (@1stOncology)
    PARP Biomarker • BRCA Biomarker • BRCA Companion diagnostic • PARP Companion diagnostic • Companion diagnostic
    |
    FoundationOne® CDx
    |
    Lynparza (olaparib)
    5years
    3 more FDA approvals for molecular testing, this time tumor type-specific: Fast and Furious. FDA Approves FoundationOne®Liquid CDx for Three Targeted Therapies That Treat Advanced Ovarian, Breast and Non-Small Cell Lung Cancer https://t.co/Fpip9M94vi (@drgandara)
    FDA event
    |
    FoundationOne® CDx
    5years
    The FDA has approved #FoundationOne CDx for the identification of #NTRK gene fusions in patients with solid tumors eligible to receive #larotrectinib: https://t.co/dWdLs16UGP @alexdrilon (@KeiraSm77106890)
    FDA event • Clinical
    |
    NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK fusion
    |
    FoundationOne® CDx
    |
    Vitrakvi (larotrectinib)
    5years
    Another molecular testing approval by FDA in tumor type-agnostic fashion. FoundationOne®CDx Receives FDA-Approval for larotrectinib to Identify NTRK Fusions Across All Solid Tumors https://t.co/DZS4Tq6ueE (@drgandara)
    FDA event
    |
    NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK fusion
    |
    FoundationOne® CDx
    |
    Vitrakvi (larotrectinib)
    5years
    Plasma based NGS testing is now considered standard of care for testing of molecular mutations in #NSCLC. Terrific start to the day #LiquidBiopsy20 @drgandara discusses approvals of current assays including @GuardantHealth and @FoundationOne #LCSM @IASLC (@CharuAggarwalMD)
    Liquid biopsy • Next-generation sequencing
    |
    FoundationOne® CDx
    over5years
    #FDA Approves FoundationOne Liquid CDx for Solid Tumors @US_FDA https://t.co/CepgPqdjpY (@OncLive)
    FDA event
    |
    FoundationOne® CDx • FoundationOne® Liquid CDx
    almost6years
    "But @FoundationOne doesn’t do RNA seq and misses on fusions which are critical in GI cancers @kmody29 @GIcancerDoc @MiteshBorad" (@the_danielahn)
    FoundationOne® CDx